Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 360

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial

Open access
Fokas, Emmanouil, Schlenska-Lange, Anke, Polat, Bülent, Klautke, Gunther, Grabenbauer, Gerhard G., Fietkau, Rainer, Kuhnt, Thomas, Staib, Ludger, Brunner, Thomas, Grosu, Anca-Ligia, Kirste, Simon, Jacobasch, Lutz, Allgäuer, Michael, Flentje, Michael, Germer, Christoph-Thomas, Grützmann, Robert, Hildebrandt, Guido, Schwarzbach, Matthias, Bechstein, Wolf O., Sülberg, Heiko, Friede, Tim, Gaedcke, Jochen, Ghadimi, Michael, Hofheinz, Ralf-Dieter, Rödel, Claus, German Rectal Cancer Study Group, Imhoff, Detlef, Woeste, Guido, Habbe, Nils, Pession, Ursula, Hansmann, Martin-Leo, Wild, Peter, Falk, Stephan, Hödl, Petra, Serebrennikov, Andre, Schmeck, Sanja, Paolucci, Vittorio, Sahm, Stephan, Eichel, Martin, Römer, Giovanna, Bank, Wolfgang, Moosmann, Nicolas, Braess, Jan, Piso, Popiliu, Wiesinger, Heinrich, Kappl, Peter, Germer, Elisabeth, Warmuth-Metz, Monika, Kunzmann, Volker, Krajinovic, Katica, Rosenwald, Andreas, Bley, Thorsten, Stölzel, Ulrich, Dörne, Manfred, Renziehausen, Lutz, Boese-Land, Joachim, Meißner, Dietrich, Burchert, Dagmar, Dirsch, Olaf, Habeck, Jörg Olaf, Kirchhof, Klaus, Lamberti, Christof, Leibl, Bernhard, Gschwendtner, Andreas, Lahmer, Godehard, Lang-Welzenbach, Marga, Hohenberger, Werner, Kuhnt, Thomas, Papsdorf, Kirsten, Wittekind, Christian, Volkheimer, Christine, Wenz, Frederik, Merx, Kirsten, Post, Stefan, Gaiser, Timo, Attenberger, Ulrike, Geißler, Michael, Sträter, Jörn, Gnann, Helmut, Krämer, Stefan, Henke, Michael, Schäfer, Henning, Manegold, Philipp, Neeff, Hannes Philipp, Bronsert, Peter, Schmiegel, Wolff, Pohl, Michael, Möllecken, Christian, Adamietz, Irenäus, Viehbahn, Richard, Tannapfel, Andrea, Freiberg-Richter, Jens, Jacobi, Thorsten, Wendt, Wolfgang, Holzweißig, Klaus, Kittner, Thomas, Graeven, Ullrich, Lange, Christiane, Kania, Ulrich, Rösler, Elisabeth, Ortloff, Harold, Müller-Leisse, Christoph, Folprecht, Gunnar, Ubbelohde, Ulrike, Baretton, Gustavo, Kölbl, Oliver, Steger, Felix, Hofstädter, Ferdinand, Schlitt, Hans Jürgen, Stroszczynski, Christian, Binnebösel, Marcel, Eble, Michael J., Lüdde, Tom, Knüchel-Clarke, Ruth, Bruners, Philipp, Küchenmeister, Ute, Klar, Ernst, Erbesdolber, Andreas, Halm, Ulrich, Zachäus, Markus, Schneider, Eckhardt, Schmidt, Thomas, Köhne, Claus-Henning, Rosin, Bernd, Willborn, Kay C., Henke, Rolf-Peter, Griesinger, Frank, Flach, Hagen · 2022 · JAMA Oncology

Abstract

IMPORTANCE: Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established. OBJECTIVE: To report the long-term results of the secondary end points prespecified in the Randomized Phase 2 Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy (CAO/ARO/AIO-12 trial) for Locally Advanced Rectal Cancer. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial included 311 patients who were recruited from the accrued CAO/ARO/AIO-12 trial population from June 15, 2015, to January 31, 2018, from 18 centers in Germany. Patients with cT3-4 and/or node-positive rectal adenocarcinoma were included in the analysis. Data were analyzed from June 15, 2015, to January 31, 2018. The follow-up analysis was conducted between January 31, 2018, and November 30, 2020. INTERVENTIONS: Patients were randomly assigned to group A for 3 cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy), or to group B for CRT before chemotherapy. Total mesorectal excision was scheduled on day 123 after the start of total neoadjuvant therapy in both groups. MAIN OUTCOMES AND MEASURES: The end points assessed in this secondary analysis included long-term oncologic outcomes, chronic toxicity, patient-reported outcome measures for global health status (GHS) and quality of life (QoL), and the Wexner stool incontinence score. RESULTS: Of the 311 patients enrolled, 306 were evaluable, including 156 in group A (mean [SD] age, 60 [11] years; 106 men [68%]) and 150 in group B (mean [SD] age, 62 [10] years; 100 men [67%]). After a median follow-up of 43 months (range, 35-60 months), the 3-year disease-free survival was 73% in both groups (hazard ratio, 0.95; 95% CI, 0.63-1.45, P = .82); the 3-year cumulative incidence of locoregional recurrence (6% vs 5%, P = .67) and distant metastases (18% vs 16%, P = .52) were not significantly different. Chronic toxicity grade 3 to 4 occurred in 10 of 85 patients (11.8%) in group A and 8 of 66 patients (9.9%) in group B at 3 years. The GHS/QoL score decreased after total mesorectal excision but returned to pretreatment levels 1 year after randomization with no difference between the groups. Stool incontinence deteriorated 1 year after randomization in both groups and only improved slightly at 3 years, but never reached baseline levels. CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL, or stool incontinence and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02363374.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2021.5445

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Metadata

Authors
Fokas, E., Schlenska-Lange, A., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., Kirste, S., Jacobasch, L., Allgäuer, M., Flentje, M., Germer, C.-T., Grützmann, R., Hildebrandt, G., Schwarzbach, M., Bechstein, W. O., Sülberg, H., Friede, T., Gaedcke, J., Ghadimi, M., Hofheinz, R.-D., Rödel, C., German Rectal Cancer Study Group, Imhoff, D., Woeste, G., Habbe, N., Pession, U., Hansmann, M.-L., Wild, P., Falk, S., Hödl, P., Serebrennikov, A., Schmeck, S., Paolucci, V., Sahm, S., Eichel, M., Römer, G., Bank, W., Moosmann, N., Braess, J., Piso, P., Wiesinger, H., Kappl, P., Germer, E., Warmuth-Metz, M., Kunzmann, V., Krajinovic, K., Rosenwald, A., Bley, T., Stölzel, U., Dörne, M., Renziehausen, L., Boese-Land, J., Meißner, D., Burchert, D., Dirsch, O., Habeck, J. O., Kirchhof, K., Lamberti, C., Leibl, B., Gschwendtner, A., Lahmer, G., Lang-Welzenbach, M., Hohenberger, W., Kuhnt, T., Papsdorf, K., Wittekind, C., Volkheimer, C., Wenz, F., Merx, K., Post, S., Gaiser, T., Attenberger, U., Geißler, M., Sträter, J., Gnann, H., Krämer, S., Henke, M., Schäfer, H., Manegold, P., Neeff, H. P., Bronsert, P., Schmiegel, W., Pohl, M., Möllecken, C., Adamietz, I., Viehbahn, R., Tannapfel, A., Freiberg-Richter, J., Jacobi, T., Wendt, W., Holzweißig, K., Kittner, T., Graeven, U., Lange, C., Kania, U., Rösler, E., Ortloff, H., Müller-Leisse, C., Folprecht, G., Ubbelohde, U., Baretton, G., Kölbl, O., Steger, F., Hofstädter, F., Schlitt, H. J., Stroszczynski, C., Binnebösel, M., Eble, M. J., Lüdde, T., Knüchel-Clarke, R., Bruners, P., Küchenmeister, U., Klar, E., Erbesdolber, A., Halm, U., Zachäus, M., Schneider, E., Schmidt, T., Köhne, C.-H., Rosin, B., Willborn, K. C., Henke, R.-P., Griesinger, F., & Flach, H.
Venue
JAMA Oncology
Published
2022-01-20
Volume
8
Issue
1
Pages
e215445
ISSN
2374-2437 (ISSN-L)
OpenAlex
W3211715598
Cited by
360
References
22
FWCI
17.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2021.5445
The paper
Fokas, E., Schlenska-Lange, A., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., Kirste, S., Jacobasch, L., Allgäuer, M., Flentje, M., Germer, C.-T., Grützmann, R., Hildebrandt, G., Schwarzbach, M., Bechstein, W. O., . . . Flach, H. (2022). Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.5445

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.